Gleevec — CareFirst (Caremark)
Chronic Graft-Versus-Host Disease (cGVHD)
Initial criteria
- Requested medication used as subsequent therapy in combination with systemic corticosteroids
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months